Navigation Links
Mylan Launches First Generic Version of Vfend® Tablets
Date:2/15/2011

PITTSBURGH, Feb. 15, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Voriconazole Tablets, 50 mg and 200 mg, under a previously announced settlement and license agreement with Pfizer Inc. Mylan was the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for Voriconazole Tablets and was awarded 180 days of marketing exclusivity.  

Voriconazole Tablets are the generic version of Pfizer's Vfend® Tablets, a triazole antifungal agent. This product had U.S. sales of approximately $186 million for the 12 months ending Dec. 31, 2010, according to IMS Health.

Currently, Mylan has 170 ANDAs pending FDA approval representing $97.7 billion in annual sales, according to IMS Health. Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $24.2 billion in annual brand sales, for the 12 months ending June 30, 2010, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Receives Approval for First-to-File Generic Sular® Extended-Release Tablets
2. Mylans Matrix Obtains License for Promising HIV/AIDS Treatment
3. Mylan Announces Lipitor® Settlement Agreement
4. Mylan Announces Caduet® Settlement Agreement
5. Mylans Matrix Receives Approval for Generic Version of Protonix® Delayed-release Tablets
6. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Lamivudine and Zidovudine Tablets, 30 mg/60 mg
7. Mylan Receives Approval for Generic Version of Precose® Tablets
8. Mylan Announces Voluntary De-listing of 1.25% Senior Convertible Notes Due 2012 from Nasdaq
9. Mylans Dey Pharma Partners with Meda to Market EpiPen® Auto-Injector in Europe
10. Mylan Confirms First-to-File Patent Challenge Relating to Orapred ODT®
11. Mylan Receives Approval for Generic Version of Adalat® CC Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... OSWEGO, Ore. , Dec. 5, 2016   ... the BioInsight clinical study. The study evaluates the safety ... insertion procedure in an office setting. BioMonitor ... ® technology that is placed underneath a patient,s ... fibrillation and syncope (fainting). Atrial fibrillation is a leading ...
(Date:12/5/2016)... PITTSBURGH , Dec. 5, 2016  Wellbridge Health and ... innovative digital health solutions to Medicare and Medicaid plan members ... effort targeted at the unique needs of this group of ... on social work philosophies to provide insight into members, daily ... , ...
(Date:12/5/2016)... N.J. , Dec. 5, 2016  Daiichi ... preliminary safety and efficacy data from a phase ... MDM2 inhibitor, suggesting that DS-3032 may be a ... myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). ... the phase 1 study of DS-3032 were presented in ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... December 03, 2016 , ... While James Earl Jones is known for myriad ... a show called "Front Page". One of the forthcoming episodes examines mammogram techniques; a ... plummeted in large part due to early detection. Like any other disease, treatments have ...
(Date:12/4/2016)... ... December 03, 2016 , ... Penrose Senior Care Auditors® was ... Tuesday evening at the 26th Annual SMU Cox Dallas 100™ Awards Ceremony and ... Institute for Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, honors the ingenuity, ...
(Date:12/4/2016)... ... December 04, 2016 , ... Patients who wish ... take advantage of a cosmetic procedure known as Carbon Dioxide (C02) Fractional ... appearance of age spots, fine lines, uneven coloration, wrinkles, scarring, skin laxity ...
(Date:12/4/2016)... ... ... Responsible dental care hinges on regular brushing of the teeth. However, just brushing ... inspired an inventor from Las Vegas, Nev., to design the BRUSH PROPER. , ... bad techniques of brushing the teeth in order to prevent cavities," he said. "Children ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and ... will speak at the American Conference Institute’s 21st Drug & Medical Device Litigation ... Lead Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device ...
Breaking Medicine News(10 mins):